Compare Marathon Petroleum Corp (MPC) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Marathon Petroleum Corp trades at $489.98 (market cap $133.95B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Marathon Petroleum Corp is far larger — about 137.7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Marathon Petroleum Corp pays a 0.84% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marathon Petroleum Corp for 53 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| MPC | MRVI | |
|---|---|---|
Market Cap | $133.95B | $972.90M |
Volume | 1,644,329 | 4,325,710 |
Sector | Energy | Health |
52-Week High | $484.92 | $9.00 |
52-Week Low | $162.63 | $2.83 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | $160.47B | $1.08B |
Dividend Yield | 0.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $484.92, up 5.69% today, reflecting strong momentum amid bullish technical signals and consistent earnings beats. The stock shows robust profitability with a 47.9% ROE and trades at a reasonable P/E of 16.54. Recent news highlights refining margin strength and positive analyst sentiment, though it faces risks from potential diesel export policy shifts.
The outlook remains positive given tight refining markets and earnings growth projections, but investors should weigh policy risks and high debt levels. Wall Street consensus is strongly bullish with a $444.30 price target, though the current price exceeds this, suggesting near-term caution may be warranted despite long-term fundamentals.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
